EU Regulators Recommend Approval for TransCon CNP
The treatment for achondroplasia in children is expected to reach the German market by early 2027.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Should regulatory bodies accelerate the approval process for new rare disease therapies?
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for TransCon CNP to treat achondroplasia in children. This follows the drug's FDA approval in the United States earlier in 2026.
Why it matters
The recommendation marks a significant regulatory milestone for treating the underlying genetic imbalance in achondroplasia, a condition affecting over 250,000 individuals globally. It moves the drug closer to clinical availability for patients in Europe.
TransCon CNP is a prodrug of C-type natriuretic peptide designed for once-weekly administration. It provides continuous systemic exposure to counteract overactive FGFR3 signaling, which is the primary driver of the condition's pathology.
The players
Ascendis Pharma
A Denmark-based biopharmaceutical company focused on developing prodrug therapies using its proprietary TransCon technology platform.
European Medicines Agency
The European Union agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
The details
TransCon CNP acts as a prodrug—an inactive compound that becomes biologically active only after metabolism within the body—to deliver C-type natriuretic peptide (CNP). By maintaining steady levels of this peptide, the treatment helps normalize signaling pathways disrupted by overactive FGFR3, a receptor that typically inhibits bone growth. Clinical evidence supporting this authorization includes three randomized, double-blind, placebo-controlled trials along with three years of open-label extension data.
Timeline
November 17, 2025: Publication of ApproaCH Trial data in JAMA Pediatrics.
February 2026: FDA approved TransCon CNP in the United States.
October 16, 2026: CHMP adopted positive opinion for marketing authorization.
Q4 2026: Expected final European Commission decision.
Q1 2027: Expected first EU launch in Germany.
The Tech Race
This regulatory progress follows the clinical trajectory established by the pivotal ApproaCH Trial. The company continues to compete in the specialized segment for skeletal dysplasias by building on demonstrated long-term safety and efficacy data.
Children aged two years and older with open epiphyses are the intended recipients of this treatment. Clinical access in Europe is expected to begin in Germany during the first quarter of 2027, pending the final European Commission decision.
The takeaway
The EMA recommendation confirms the therapeutic potential of weekly CNP therapy for young patients with achondroplasia. Stakeholders should monitor the European Commission's formal decision in Q4 2026 to confirm the regional rollout schedule.
What happens next
The European Commission is expected to issue a final decision regarding marketing authorization in Q4 2026.
Further reading
For more on the latest advancements in drug development, visit Biotech.
Live Poll
Should regulatory bodies accelerate the approval process for new rare disease therapies?
